New FDA commissioner Scott Gottlieb has outlined his plans to tackle the opioid abuse epidemic afflicting the US, saying doctors should be better educated about the risks of prescribing mon
Sandoz has signed a potential $293 million agreement to develop and market Durect’s Posimir, an extended-release, locally-acting, non-opioid painkiller in the US.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
